Opinions
Jim Cramer - Mad Money
Prometheus Biosciences
RXDX-Q
BUY
Dec 09, 2022
They make drugs to treat inflammatory bowel diseases, a big market. Last Wednesday they announced strong phase 2 trial data for a leading IBD drug. Shares soared 166% on Wednesday. This drug will mae RXDX a major pharma.
$110.200
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.